Literature DB >> 11774285

CD151 enhances cell motility and metastasis of cancer cells in the presence of focal adhesion kinase.

Masashi Kohno1, Hitoshi Hasegawa, Masayuki Miyake, Tadashi Yamamoto, Shigeru Fujita.   

Abstract

We have examined the role of the protein CD151 in cell motility, invasion and metastasis of cancer cells by using CD151-overexpressing cells prepared by transfection of CD151 cDNA into three cancer cell lines established from different origins; a human colon cancer RPMI4788, a human glioblastoma A172 and a human fibrosarcoma HT1080. Invasion into Matrigel and cell motility of all 3 CD151-overexpressing cancer cells were enhanced significantly when compared to control parental cells. Pulmonary metastasis of 2 metastatic CD151-overexpressing cancer cell lines, RPMI4788/CD151 and HT1080/CD151, was higher than that of control parental cells and was markedly inhibited by anti-CD151 monoclonal antibody (MAb), SFA1.2B4. To examine whether focal adhesion kinase (FAK) is associated with promotion of cell motility and invasion of cancer cells through CD151, we transfected human CD151 cDNA into FAK (+/+) or FAK (-/-) fibroblasts that were isolated from embryos in FAK-deficient mice and compared invasion into Matrigel and cell motility between each CD151-transfected cells and controls. The invasion into Matrigel and cell motility of CD151-transfected FAK (+/+) fibroblasts increased significantly above those of parental cells and were inhibited by anti-CD151 MAb, whereas those of CD151-transfected FAK (-/-) fibroblasts were not enhanced at all and were not blocked by anti-CD151 MAb. These findings indicate that the CD151 molecule enhances cell motility, invasion and metastasis of cancer cells and that FAK is needed for these events through CD151. Copyright 2001 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11774285     DOI: 10.1002/ijc.1605

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  40 in total

Review 1.  Tetraspanins and tumor progression.

Authors:  Mekel M Richardson; Lisa K Jennings; Xin A Zhang
Journal:  Clin Exp Metastasis       Date:  2010-12-24       Impact factor: 5.150

2.  Potentiation of the ligand-binding activity of integrin alpha3beta1 via association with tetraspanin CD151.

Authors:  Ryoko Nishiuchi; Noriko Sanzen; Shigeyuki Nada; Yasuhiro Sumida; Yoshinao Wada; Masato Okada; Junichi Takagi; Hitoshi Hasegawa; Kiyotoshi Sekiguchi
Journal:  Proc Natl Acad Sci U S A       Date:  2005-01-26       Impact factor: 11.205

Review 3.  Regulation of FAK Activity by Tetraspan Proteins: Potential Clinical Implications in Cancer.

Authors:  Yu Qin; Shabnam Mohandessi; Lynn Gordon; Madhuri Wadehra
Journal:  Crit Rev Oncog       Date:  2015

Review 4.  Tetraspanins in cell migration.

Authors:  Xupin Jiang; Jiaping Zhang; Yuesheng Huang
Journal:  Cell Adh Migr       Date:  2015-06-19       Impact factor: 3.405

5.  A critical role for tetraspanin CD151 in alpha3beta1 and alpha6beta4 integrin-dependent tumor cell functions on laminin-5.

Authors:  Nicole E Winterwood; Afshin Varzavand; Marit N Meland; Leonie K Ashman; Christopher S Stipp
Journal:  Mol Biol Cell       Date:  2006-03-29       Impact factor: 4.138

Review 6.  Tetraspanin proteins promote multiple cancer stages.

Authors:  Martin E Hemler
Journal:  Nat Rev Cancer       Date:  2014-01       Impact factor: 60.716

7.  CD151 gene delivery after myocardial infarction promotes functional neovascularization and activates FAK signaling.

Authors:  Houjuan Zuo; Zhengxiang Liu; Xiaochun Liu; Jun Yang; Tao Liu; Sha Wen; Xin A Zhang; Katherine Cianflone; Daowen Wang
Journal:  Mol Med       Date:  2009-06-18       Impact factor: 6.354

8.  Tetraspanin CD151 stimulates adhesion-dependent activation of Ras, Rac, and Cdc42 by facilitating molecular association between β1 integrins and small GTPases.

Authors:  In-Kee Hong; Doo-Il Jeoung; Kwon-Soo Ha; Young-Myeong Kim; Hansoo Lee
Journal:  J Biol Chem       Date:  2012-07-25       Impact factor: 5.157

9.  CD151 expression is frequent but unrelated to clinical outcome in head and neck cancer.

Authors:  Julie C Nienstedt; Alexander Gröbe; Patrick Lebok; Franziska Büscheck; Till Clauditz; Ronald Simon; Asmus Heumann; Guido Sauter; Christoph Moebius; Adrian Münscher; Rainald Knecht; Marco Blessmann; Max Heiland; Christina Pflug
Journal:  Clin Oral Investig       Date:  2016-07-21       Impact factor: 3.573

10.  Identification and functional characterization of hemorphins VV-H-7 and LVV-H-7 as low-affinity agonists for the orphan bombesin receptor subtype 3.

Authors:  Hans-Peter Lammerich; Annette Busmann; Christian Kutzleb; Martin Wendland; Petra Seiler; Claudia Berger; Peter Eickelmann; Markus Meyer; Wolf-Georg Forssmann; Erik Maronde
Journal:  Br J Pharmacol       Date:  2003-04       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.